We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

68 hedge funds and large institutions have $1.21B invested in ARS Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

10% more funds holding

Funds holding: 62 → 68 (+6)

9.33% more ownership

Funds ownership: 70.26% → 79.6% (+9.3%)

7% more capital invested

Capital invested by funds: $1.13B → $1.21B (+$79.1M)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.19%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
29
Increased
12
Reduced
12
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$49M
3
BlackRock
BlackRock
New York
+$39.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.6M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$9.72M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$10.1M
2
LGM
Logos Global Management
California
-$8.28M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.4M
4
Millennium Management
Millennium Management
New York
-$6.12M
5
Goldman Sachs
Goldman Sachs
New York
-$4.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
$241K +$262K +5,527 New
VOYA Investment Management
52
VOYA Investment Management
Georgia
$233K +$253K +5,350 New
Ensign Peak Advisors
53
Ensign Peak Advisors
Utah
$218K – – –
Wells Fargo
54
Wells Fargo
California
$191K +$207K +4,382 New
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$176K +$191K +4,038 New
UBS Group
56
UBS Group
Switzerland
$154K +$163K +3,446 +3,705%
SO
57
STRS Ohio
Ohio
$135K +$147K +3,100 New
Legal & General Group
58
Legal & General Group
United Kingdom
$57K +$61.3K +1,295 +9,962%
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$51K +$54.8K +1,158 New
AIP
60
Ameritas Investment Partners
Nebraska
$45K +$48.8K +1,032 New
Citigroup
61
Citigroup
New York
$37K -$674K -14,243 -94%
TRCT
62
Tower Research Capital (TRC)
New York
$29K +$31.1K +657 New
PA
63
Parallel Advisors
California
$18K +$11.8K +250 +152%
Bank of Montreal
64
Bank of Montreal
Ontario, Canada
$16K +$18.5K +390 New
US Bancorp
65
US Bancorp
Minnesota
$2K +$2.27K +48 New
CS
66
Candriam SCA
Luxembourg
$1K +$615 +13 New
AIG
67
American International Group
New York
$323 +$350K +7,393 New
Citadel Advisors
68
Citadel Advisors
Florida
– -$6.4M -138,138 Closed
Goldman Sachs
69
Goldman Sachs
New York
– -$4.07M -87,813 Closed
GPP
70
Great Point Partners
Connecticut
– -$3.24M -70,000 Closed
MIM
71
Monashee Investment Management
Massachusetts
– -$2.78M -60,000 Closed
MWNA
72
Marshall Wace North America
New York
– -$2.72M -58,788 Closed
UBS AM
73
UBS AM
Illinois
– -$2.67M -57,575 Closed
FCM
74
Farallon Capital Management
California
– -$2.21M -47,620 Closed
PVI
75
Pura Vida Investments
New York
– -$2.08M -45,000 Closed
1 2
3
4

SPRY Hedge Fund Activity: Q1 2021 in Review

68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2021, worth a combined $1.21B — up 7% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SPRY positions and 23 closed out — a net gain of 6 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $65.5M. The largest seller was Nantahala Capital Management, cutting an estimated $10.1M.

  • 68 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2021, up from 62 in Q4 2020.
  • Funds reported $1.21B of ARS Pharmaceuticals stock for Q1 2021, up 7% quarter-over-quarter.
  • 29 funds opened new ARS Pharmaceuticals positions in Q1 2021 and 23 closed out, a net change of +6 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $65.5M added.
  • The largest ARS Pharmaceuticals seller in Q1 2021 was Nantahala Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2021.